The estimated Net Worth of Anthony Clarke is at least $606 Thousand dollars as of 28 April 2022. Anthony Clarke owns over 1,000 units of Achieve Life Sciences stock worth over $16,059 and over the last 7 years he sold ACHV stock worth over $0. In addition, he makes $589,657 as Chief Science Officer at Achieve Life Sciences.
Anthony has made over 1 trades of the Achieve Life Sciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 1,000 units of ACHV stock worth $4,280 on 28 April 2022.
The largest trade he's ever made was exercising 1,000 units of Achieve Life Sciences stock on 28 April 2022 worth over $4,280. On average, Anthony trades about 111 units every 0 days since 2017. As of 28 April 2022 he still owns at least 3,752 units of Achieve Life Sciences stock.
You can see the complete history of Anthony Clarke stock trades at the bottom of the page.
Dr. Anthony Clarke serves as Chief Science Officer of the Company. He has served as our President and Chief Scientific Officer and director since August 2017. Prior to the Merger, Dr. Clarke served as Achieve Life Science, Inc.’s Chief Scientific Officer and as a member of Achieve Life Science, Inc.’s board of directors since 2015. Dr. Clarke is a founder and director of Ricanto Limited since 2009. From 2016 to the present, Dr. Clarke has been Chief Scientific Officer of Renown Pharma Limited. Dr. Clarke was Chief Scientific Officer of Huxley Pharmaceuticals, Inc. during 2009, prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Prior to Achieve, Dr. Clarke served as Chief Scientific Officer of Brabant Pharma Limited from 2013 to 2014 prior its acquisition by Zogenix Inc. Dr. Clarke served as Company Secretary of Alexza UK Ltd. and as Vice President International Development Operations of Alexza Pharmaceuticals Inc., a pharmaceutical development company, holding both positions from 2008 to 2009. Dr. Clarke served as the Vice President, Clinical Research and Regulatory Affairs at Amarin Corporation from 2005 to 2008. In addition, Dr. Clarke was Senior Director, Clinical and Regulatory Affairs, of Cephalon Europe and as Senior Director, Worldwide Pain Management, of Cephalon, Inc. from 2000 to 2004. Dr. Clarke held a number of management roles in other pharmaceutical companies prior to 2000 as well as academic posts and honorary academic posts. Dr. Clarke holds a Bachelor’s degree in Pharmacology from the University of Sunderland and a Ph.D. in psychopharmacology from the University of London. He was a Fellow of the Royal Statistical Society (UK) and is a current Fellow of the Royal Society of Medicine (UK). The determination was made that Dr. Clarke should serve on our Board of Directors due to his years of experience in the biotechnology industry, which enable him to contribute important strategic insights to the Board of Directors.
As the Chief Science Officer of Achieve Life Sciences, the total compensation of Anthony Clarke at Achieve Life Sciences is $589,657. There are 4 executives at Achieve Life Sciences getting paid more, with Richard Stewart having the highest compensation of $796,644.
Anthony Clarke is 64, he's been the Chief Science Officer of Achieve Life Sciences since 2020. There are 3 older and 11 younger executives at Achieve Life Sciences. The oldest executive at Achieve Life Sciences Inc. is Donald Joseph, 66, who is the Independent Director.
Anthony's mailing address filed with the SEC is 22722 29TH DR SE, SUITE 100, BOTHELL, WA, 98021.
Over the last 7 years, insiders at Achieve Life Sciences have traded over $972,224 worth of Achieve Life Sciences stock and bought 70,500 units worth $224,475 . The most active insiders traders include Capital, Llc Armistice Capi..., Vaughn B Himes, and Jay M Moyes. On average, Achieve Life Sciences executives and independent directors trade stock every 65 days with the average trade being worth of $63,759. The most recent stock trade was executed by Jerry Wan on 19 April 2024, trading 5,625 units of ACHV stock currently worth $24,075.
achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.
Achieve Life Sciences executives and other stock owners filed with the SEC include: